The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free ...

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised ...

ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, ...

Research shows that the drug tazemetostat – which is already approved for use in patients with one type of B-cell lymphoma – ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

The US Food and Drug Administration has approved US biotech Incyte’s (Nasdaq: INCY) Monjuvi (tafasitamab-cxix) with ...